Lowering the burden of Ebola
In response to the Ebola epidemic in West Africa, the Horizon 2020 EU research initiative ‘EVIDENT’ was launched in November 2014. Equipped with a budget of € 1.7 million, the two-year EVIDENT project provided a research platform which built upon the success of the European Mobile Laboratory consortium (EMLab) that was performing Ebola Virus Disease (EVD) diagnostics in affected West African countries since March 2014. EVIDENT’s mandate was to scientifically exploit specimens from EVD patients collected as part of the outbreak response in Guinea, Liberia and Sierra Leone and to gather critical knowledge on B and T cell immunology, biomarkers, virus evolution, virulence determinants, and transmission of Ebola Virus.
News & Events
ERINHA conference: launching the European Research Infrastructure on Highly Pathogenic Agents’ scientific strategy
The European Research Infrastructure on Highly Pathogenic Agents (ERINHA) will be holding a one-day...
After the end of the EVIDENT project on 30 October 2016, the final project report was submitted to...
Deep Sequencing of RNA from Blood and Oral Swab Samples Reveals the Presence of Nucleic Acid from a Number of Pathogens in Patients with Acute Ebola Virus Disease and Is Consistent with Bacterial Translocation across the Gut
mSphere Volume 2, Issue 4 , DOI: 10.1128/mSphereDirect.00325-17
Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus
Genome Biology (2017) 18:4, DOI: 10.1186/s13059-016-1137-3